Caris Life Sciences,
Caris’ AI-powered predictor MI FOLFOXai demonstrates 71% difference in overall survival for mCRC patients published in @CCR_AACR.
Caris’ AI-powered predictor MI FOLFOXai demonstrates 71% difference in overall survival for mCRC patients published in @CCR_AACR.
Caris' AI-powered predictor helps gauge which metastatic colorectal cancer patients will benefit from treatment with current…
Validation studies published in @CCR_AACR illustrate a 71% difference in overall survival for mCRC patients using Caris' AI-power…
Validated across two independent studies in @CCR_AACR, MI FOLFOXai helps physicians better determine the relative benefit…
Caris’ AI-powered predictor helps gauge which metastatic colorectal cancer patients will benefit from treatment with current…